参考文献[1]
RothGA, JohnsonC, AbajobirA, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015[J]. J Am Coll Cardiol, 2017, 70(1):1-25. .
[2]
SaklayenMG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018, 20(2):12. .
[3]
RussoGI, CiminoS, CastelliT, et al. Benign prostatic hyperplasia, metabolic syndrome and non-alcoholic fatty liver disease: is metaflammation the link?[J]. Prostate, 2016, 76(16):1528-1535. .
[4]
FanJG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J]. J Gastroenterol Hepatol, 2013, 28Suppl 1:11-17. .
[5]
CaldwellS, ArgoC. The natural history of non-alcoholic fatty liver disease[J]. Dig Dis, 2010, 28(1): 162-168. .
[6]
Neuschwander-TetriBA, ClarkJM, BassNM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease[J]. Hepatology, 2010, 52(3):913-924. .
[7]
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3):163-166. .
[8]
BallestriS, LonardoA, BonapaceS, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(7):1724-1745. .
[9]
OniET, AgatstonAS, BlahaMJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?[J]. Atherosclerosis, 2013, 230(2):258-267. .
[10]
FrancqueSM, van der GraaffD, KwantenWJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications[J]. J Hepatol, 2016, 65(2):425-443. .
[11]
TargherG, DayCP, BonoraE. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 363(14):1341-1350. .
[12]
LauridsenBK, StenderS, KristensenTS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals[J]. Eur Heart J, 2018, 39(5):385-393. .
[13]
LiuY, ZhongGC, TanHY, et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis[J]. Sci Rep, 2019, 9(1):11124. .
[14]
BrouwersM, SimonsN, StehouwerC, et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality[J]. Diabetologia, 2020, 63(2):253-260. .
[15]
KumarA, CannonCP. Acute coronary syndromes: diagnosis and management, part I[J]. Mayo Clin Proc, 2009, 84(10):917-938. .
[16]
DumitrascuDL, NeumanMG. Non-alcoholic fatty liver disease: an update on diagnosis[J]. Clujul Med, 2018, 91(2):147-150. .
[17]
LabenzC, HuberY, MichelM, et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany[J]. Dig Dis Sci, 2020, 65(7):2112-2119. .
[18]
MontemezzoM, AlTurkiA, StahlschmidtF, et al. Nonalcoholic fatty liver disease and coronary artery disease: big brothers in patients with acute coronary syndrome[J]. ScientificWorldJournal, 2020, 2020:8489238. .
[19]
SinnDH, KangD, ChangY, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study[J]. J Gastroenterol Hepatol, 2020, 35(5):833-839. .
[20]
KimJH, MoonJS, ByunSJ, et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study[J]. Cardiovasc Diabetol, 2020, 19(1):51. .
[21]
OlubamwoOO, VirtanenJK, VoutilainenA, et al. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction[J]. Eur J Gastroenterol Hepatol, 2018, 30(9):1047-1054. .
[22]
DunnMA, BehariJ, RogalSS, et al. Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes[J]. Liver Int, 2013, 33(10):1575-1582. .
[23]
AlexanderM, LoomisAK, van der LeiJ, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults[J]. BMJ, 2019, 367:l5367. .
[24]
GhouriN, PreissD, SattarN. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data[J]. Hepatology, 2010, 52(3):1156-1161. .
[25]
WongM, YapJ, SultanaR, et al. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis[J]. Open Heart, 2021, 8(2): e001850. .
[26]
MohantySR, TroyTN, HuoD, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease[J]. J Hepatol, 2009, 50(4):797-804. .
[27]
RichNE, OjiS, MuftiAR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2018, 16(2):198-210.e2. .
[28]
PanJJ, FallonMB. Gender and racial differences in nonalcoholic fatty liver disease[J]. World J Hepatol, 2014, 6(5):274-283. .
[29]
WongRJ, AhmedA. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations[J]. World J Hepatol, 2014, 6(5):263-273. .
[30]
PerryAC, ApplegateEB, JacksonML, et al. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables[J]. J Appl Physiol (1985), 2000, 89(2):636-643. .
[31]
AllisonMA, BudoffMJ, NasirK, et al. Ethnic-specific risks for atherosclerotic calcification of the thoracic and abdominal aorta (from the Multi-Ethnic Study of Atherosclerosis)[J]. Am J Cardiol, 2009, 104(6):812-817. .
[32]
KhuranaC, RosenbaumCG, HowardBV, et al. Coronary artery calcification in black women and white women[J]. Am Heart J, 2003, 145(4):724-729. .
[33]
PuchnerSB, LuMT, MayrhoferT, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT Ⅱ trial[J]. Radiology, 2015, 274(3):693-701. .
[34]
ÖztürkH, GümrükçüoğluHA, YamanM, et al. Hepatosteatosis and carotid intima-media thickness in patients with myocardial infarction[J]. J Med Ultrason (2001), 2016, 43(1):77-82. .
[35]
AgaçMT, KorkmazL, CavusogluG, et al. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study[J]. Angiology, 2013, 64(8):604-608. .
[36]
ByrneCD, TargherG. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease[J]. Arterioscler Thromb Vasc Biol, 2014, 34(6):1155-1161. .
[37]
SinnDH, KangD, ChangY, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study[J]. Gut, 2017, 66(2):323-329. .
[38]
BieghsV, RensenPC, HofkerMH, et al. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages[J]. Atherosclerosis, 2012, 220(2):287-293. .
[39]
AnsteeQM, TargherG, DayCP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(6):330-344. .
[40]
LeeYJ, ShimJY, MoonBS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2012, 57(1):196-203. .
[41]
VanWagnerLB, WilcoxJE, ColangeloLA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study[J]. Hepatology, 2015, 62(3):773-783. .
[42]
TsabanG, WolakA, Avni-HassidH, et al. Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss[J]. Am J Clin Nutr, 2017, 106(4):984-995. .
[43]
MahabadiAA, BergMH, LehmannN, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study[J]. J Am Coll Cardiol, 2013, 61(13):1388-1395. .
[44]
MahabadiAA, LehmannN, KälschH, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study[J]. JACC Cardiovasc Imaging, 2014, 7(9):909-916. .
[45]
GoldbergIJ, TrentCM, SchulzePC. Lipid metabolism and toxicity in the heart[J]. Cell Metab, 2012, 15(6):805-812. .
[46]
MantovaniA, PernigoM, BergaminiC, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease[J]. Metabolism, 2015, 64(8):879-887. .
[47]
DesprésJP. Body fat distribution and risk of cardiovascular disease: an update[J]. Circulation, 2012, 126(10):1301-1313. .
[48]
PackerM. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium[J]. J Am Coll Cardiol, 2018, 71(20):2360-2372. .
[49]
EsteveE, RicartW, Fernández-RealJM. Dyslipidemia and inflammation: an evolutionary conserved mechanism[J]. Clin Nutr, 2005, 24(1):16-31. .
[50]
OrmazabalV, NairS, ElfekyO, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17(1):122. .
[51]
KotronenA, Joutsi-KorhonenL, SevastianovaK, et al. Increased coagulation factor Ⅷ, Ⅸ, Ⅸ and Ⅻ activities in non-alcoholic fatty liver disease[J]. Liver Int, 2011, 31(2):176-183. .
[52]
Aron-WisnewskyJ, VigliottiC, WitjesJ, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(5):279-297. .
[53]
DemirM, LangS, MartinA, et al. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: ready for prime time?[J]. J Gastroenterol Hepatol, 2020, 35(11):1969-1977. .